A phase IIa study of Prexigebersen in accelerated and blast phase chronic myeloid leukemia (CML) patients.
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2018
At a glance
- Drugs Dasatinib (Primary) ; Prexigebersen (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 27 Dec 2018 According to a Bio-Path Holdings media release, For 2019, additional sites are planned to be added and enrollment planned to be opened across both phases of the disease, including imatinib-resistant chronic phase patients.
- 12 Jan 2018 New trial record
- 29 Dec 2017 According to a Bio-Path Holdings media release, the trial is being conducted at The University of Texas MD Anderson Cancer Center.